[Prodigiozan and antibiotics].
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000937:Antigen-Antibody Reactions / Q000187:drug effects; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001991:Bronchitis / Q000188:drug therapy; D002764:Cholecystitis / Q000188:drug therapy; D003092:Colitis / Q000188:drug therapy; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy; D006506:Hepatitis A / Q000188:drug therapy; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D007251:Influenza, Human / Q000517:prevention & control; D009374:Neoplasms, Experimental / Q000188:drug therapy; D009784:Occupational Diseases / Q000188:drug therapy; D010510:Periodontal Diseases / Q000188:drug therapy; D010587:Phagocytosis / Q000187:drug effects; D010913:Pituitary-Adrenal System / Q000187:drug effects; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy; D011353:Prodigiosin / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy; D011704:Pyelonephritis / Q000188:drug therapy; D011837:Radiation-Protective Agents / Q000627:therapeutic use; D013530:Surgical Wound Infection / Q000188:drug therapy; D014069:Tonsillitis / Q000188:drug therapy; D014777:Virus Diseases / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D011837:Radiation-Protective Agents; D011353:Prodigiosin
Prodigiozan i antibiotiki.